As it stated in usatoday
Zika vaccine waits on Congress
Zika vaccine waits on Congress
Virus is devastating to the small number of people getting infected during pregnancyAnthony Fauci, director of the National Institute of Allergy and Infectious Diseases, meets with the USA TODAY Editorial Board on Aug. 29, 2016.(Photo: Jasper Colt, USAT)Congress returns to Washington this week and is expected to take up the Obama administration's urgent request for more money to fight the Zika virus.Dr. Anthony Fauci, America's point man on infectious diseases, spoke with the USA TODAY Editorial Board last week about the latest Zika developments, the need for more funding and the search for a vaccine.
as well bostonglobe
Cambridge company joins effort to develop Zika vaccine
Cambridge company joins effort to develop Zika vaccine
PHARMACEUTICALSCambridge company joins effort to develop Zika vaccineTakeda Pharmaceutical Co. is joining the campaign to develop a Zika vaccine with nearly $20 million in US funding for a Cambridge-based research program.The company, which last year said it will move its global vaccines business to Cambridge from Deerfield, Ill., disclosed Thursday that it was tapped by the Biomedical Advanced Research and Development Authority to produce a vaccine to treat the virus in the United States and abroad.The initial contract of $19.8 million will fund the program into early-stage clinical trials.
besides statnews
Takeda Pharmaceuticals enters race for a Zika vaccine
Takeda Pharmaceuticals enters race for a Zika vaccine
Another major pharmaceutical company is getting into the race to produce a Zika vaccine.Takeda Vaccines of Deerfield, Ill., announced Thursday it will pursue development of a Zika vaccine with funding from the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services that spurs development of drugs, vaccines, and diagnostic tests needed to respond to or prepare for health emergencies.The initial contract with BARDA is for $19.8 million to fund preclinical research and vaccine manufacturing needed for Phase 1 clinical trials to begin in 2017.
in the same way fiercebiotech
U.S. government in $300M-plus Zika vaccine R&D deal with Takeda
U.S. government in $300M-plus Zika vaccine R&D deal with Takeda
The U.S. government's public health emergency department BARDA could pay out more than $300 million to Japanese pharma Takeda to develop a new vaccine against the Zika virus as new figures suggest billions are now at risk of the disease.Under the deal, BARDA will pay out $19.8 million to cover the costs of vaccine development through Phase I, but could also stump up $312 million should things go well.Should this happen, the Authority will fund the research through Phase III along with a filing of a BLA in the U.S. for the vax.
No comments:
Post a Comment